<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: technologies", fill: "#e52b50"},
{source: "3: technologies", target: "3: development", fill: "#e52b50"},
{source: "3: development", target: "3: new products", fill: "#e52b50"},
{source: "3: new products", target: "3: clinical market", fill: "#e52b50"},
{source: "3: clinical market", target: "3: incur significant expenses", fill: "#e52b50"},
{source: "3: incur significant expenses", target: "3: connection with", fill: "#e52b50"},
{source: "3: connection with", target: "3: commercialization programs", fill: "#e52b50"},
{source: "3: technologies", target: "7: operations", fill: "#5b92e5"},
{source: "7: operations", target: "7: fluctuated significantly", fill: "#5b92e5"},
{source: "7: fluctuated significantly", target: "7: significant fluctuations", fill: "#5b92e5"},
{source: "7: operations", target: "8: These ", fill: "#a50b5e"},
{source: "8: These ", target: "8: products offered", fill: "#a50b5e"},
{source: "8: products offered", target: "8: under collaborative agreements as", fill: "#a50b5e"},
{source: "8: under collaborative agreements as", target: "8: payments as revenues", fill: "#a50b5e"},
{source: "8: payments as revenues", target: "8: new products", fill: "#a50b5e"},
{source: "8: new products", target: "8: technologies", fill: "#a50b5e"},
{source: "8: technologies", target: "8: introduced by", fill: "#a50b5e"},
{source: "8: introduced by", target: "8: competitors", fill: "#a50b5e"},
{source: "8: competitors", target: "8: Contents ", fill: "#a50b5e"},
{source: "8: Contents ", target: "8: thirdparty intellectual property which may", fill: "#a50b5e"},
{source: "8: thirdparty intellectual property which may", target: "8: significant", fill: "#a50b5e"},
{source: "8: significant", target: "8: investments", fill: "#a50b5e"},
{source: "8: investments", target: "8: which may materially impede", fill: "#a50b5e"},
{source: "8: which may materially impede", target: "8: sell products", fill: "#a50b5e"},
{source: "8: sell products", target: "8: regulatory clearance market", fill: "#a50b5e"},
{source: "8: regulatory clearance market", target: "8: introduce new", fill: "#a50b5e"},
{source: "8: introduce new", target: "8: enhanced products on", fill: "#a50b5e"},
{source: "8: enhanced products on", target: "8: timely basis", fill: "#a50b5e"},
{source: "8: timely basis", target: "8: cost quality", fill: "#a50b5e"},
{source: "8: cost quality", target: "8: availability", fill: "#a50b5e"},
{source: "8: availability", target: "8: equipment reagents", fill: "#a50b5e"},
{source: "8: equipment reagents", target: "8: components", fill: "#a50b5e"},
{source: "8: components", target: "8: manufacture", fill: "#a50b5e"},
{source: "8: manufacture", target: "8: government funding", fill: "#a50b5e"},
{source: "8: government funding", target: "8: researchers", fill: "#a50b5e"},
{source: "8: researchers", target: "8: thirdparty", fill: "#a50b5e"},
{source: "8: thirdparty", target: "8: reimbursement", fill: "#a50b5e"},
{source: "8: These ", target: "28: manufacturing", fill: "#0087bd"},
{source: "28: manufacturing", target: "28: necessary", fill: "#0087bd"},
{source: "28: necessary", target: "28: significant commercial sales", fill: "#0087bd"},
{source: "28: manufacturing", target: "39: components", fill: "#ffd700"},
{source: "39: components", target: "39: satisfy demand", fill: "#ffd700"},
{source: "39: satisfy demand", target: "39: product on reasonable", fill: "#ffd700"},
{source: "39: product on reasonable", target: "39: financial condition", fill: "#ffd700"},
{source: "39: financial condition", target: "39: operations", fill: "#ffd700"},
{source: "39: components", target: "START_HERE", fill: "#ffd700"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Research and Consulting Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Investigate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>THIRD WAVE TECHNOLOGIES INC /WI      ITEM 1A   RISK FACTORS       RISKS RELATED TO OUR BUSINESS       WE HAD AN ACCUMULATED DEFICIT OF dlra158dtta1 <font color="blue">MILLION AT DECEMBER </font>31, 2005, AND     EXPECT TO CONTINUE TO INCUR SUBSTANTIAL OPERATING LOSSES FOR THE FORESEEABLE     FUTURE       We have had substantial operating losses since our inception in 1993, and we     expect our operating losses to <font color="blue">continue over</font> the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In  order to further develop our products and     <font color="blue">technologies</font>, including <font color="blue">development</font> of <font color="blue">new products</font> for the <font color="blue">clinical market</font>,     we will need to <font color="blue">incur <font color="blue">significant</font> expenses</font> in <font color="blue">connection with</font> our internal     research and <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> programs</font></td>
    </tr>
    <tr>
      <td>As a result, we     expect to incur annual operating losses for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In     addition, there is no assurance that we will ever <font color="blue">become profitable</font> or that     we  will  sustain  <font color="blue">profitability</font> if we do <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Should we     experience  protracted  or  unforeseen  operating  losses, our capital     <font color="blue"><font color="blue">requirements</font> would increase</font> and our <font color="blue">stock <font color="blue">price would likely decline</font></font></td>
    </tr>
    <tr>
      <td>FLUCTUATIONS IN OUR QUARTERLY REVENUES AND OPERATING RESULTS MAY NEGATIVELY     IMPACT OUR STOCK PRICE       Our revenues and results of <font color="blue">operations</font> have <font color="blue">fluctuated <font color="blue">significant</font>ly</font> in the     past and we expect <font color="blue"><font color="blue">significant</font> <font color="blue">fluctuations</font></font> to continue in the future due to     a  variety of factors, many of which are outside of our control</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>factors include:         •  the volume and timing of orders for our products;         •  changes in the mix of our <font color="blue">products offered</font>;         •  the timing of payments we receive under <font color="blue">collaborative</font> <font color="blue">agreements</font>, as     well as our ability to recognize these <font color="blue">payments as revenues</font>;         •  the number, timing and significance of <font color="blue">new products</font> and <font color="blue">technologies</font>     <font color="blue">introduced by</font> our <font color="blue">competitors</font>;                                         12       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>    •  third-party <font color="blue">intellectual</font> property, which may require <font color="blue">significant</font>     <font color="blue"><font color="blue">investment</font>s</font> in licensing or royalties, or <font color="blue">which may materially impede</font> our     ability to <font color="blue">sell products</font>;          •   our ability to develop, obtain <font color="blue">regulatory</font> clearance, market and     <font color="blue">introduce new</font> and <font color="blue">enhanced products on</font> a <font color="blue">timely basis</font>;         •  changes in the cost, quality and <font color="blue">availability</font> of equipment, reagents     and <font color="blue">components</font> required to <font color="blue">manufacture</font> or use our products;         •  <font color="blue">availability</font> of commercial and <font color="blue">government funding</font> to <font color="blue">researchers</font> who     use  our  products and services, including our single-largest research     customer in Japan; and         •  <font color="blue">availability</font> of third-party <font color="blue">reimbursement</font> to users of our clinical     products</td>
    </tr>
    <tr>
      <td><font color="blue">Research  </font>and  <font color="blue">development</font>  costs  associated  with  our  products and     <font color="blue">technologies</font>,  as well as <font color="blue">facilities</font> costs, personnel costs, marketing     programs and overhead account for a substantial portion of our operating     expenses</td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> expenses for the years ended December 31,     2005, 2004, and 2003 were dlra8dtta4 million, dlra11dtta6 million, and dlra12dtta0 million,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot reduce</font> these <font color="blue">expenses quickly</font> in the short term</td>
    </tr>
    <tr>
      <td>If     our <font color="blue">revenues decline</font> or do not grow as anticipated, we may not be able to     reduce our operating <font color="blue">expenses accordingly</font></td>
    </tr>
    <tr>
      <td>Failure to achieve anticipated     levels of revenues could <font color="blue">significant</font>ly harm our operating results for one or     more fiscal periods</td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">possibility</font> of <font color="blue">fluctuations</font> in our revenues     and  expenses,  we  believe that quarter-to-quarter comparisons of our     operating results are not a good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In     addition, our operating results in a <font color="blue">future fiscal quarter may</font> not meet the     <font color="blue">expectations</font> of <font color="blue">stock market analysts</font> and investors</td>
    </tr>
    <tr>
      <td>In that case, our stock     <font color="blue">price would likely decline</font> and <font color="blue">investors would</font> experience a decline in the     value of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>OUR TECHNOLOGIES AND COMMERCIAL PRODUCTS MAY NOT BE COMMERCIALLY VIABLE OR     SUCCESSFUL, WHICH COULD ADVERSELY AFFECT OUR BUSINESS       We are currently developing and <font color="blue">commercializing</font> a limited number of products     <font color="blue">based on</font> our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We plan to develop <font color="blue"><font color="blue">additional product</font>s</font></td>
    </tr>
    <tr>
      <td>We cannot     assure you that we will be able to complete <font color="blue">development</font> of our products that     are  currently  under  <font color="blue">development</font>  or that we will be able to develop     additional <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>In addition, for our genetic and <font color="blue">pharmacogenetic</font>     products, some of the <font color="blue">genetic <font color="blue">variations</font></font> for which we develop our products     may not be useful or <font color="blue">cost <font color="blue">effective</font></font> in <font color="blue">assisting therapeutic selection</font>,     <font color="blue">patient monitoring</font> or <font color="blue">diagnostic applications</font></td>
    </tr>
    <tr>
      <td>In this event, our sales of     products for these <font color="blue">genetic <font color="blue">variations</font></font> would diminish <font color="blue">significant</font>ly or cease,     and  we would not be able to recoup our <font color="blue">investment</font> in developing these     products</td>
    </tr>
    <tr>
      <td>Accordingly, if we fail to <font color="blue">successfully</font> develop our products and     <font color="blue">technologies</font> or if our <font color="blue">technologies</font> are not useful in the <font color="blue">development</font> of     <font color="blue">commercially successful products</font>, we may not achieve a <font color="blue"><font color="blue">competitive</font> position</font>     in the market</td>
    </tr>
    <tr>
      <td>If we fail to do so, our <font color="blue">revenues will</font> be <font color="blue">seriously harmed</font>     and  it  is  unlikely  that we will ever achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Market     </font><font color="blue">acceptance</font> of our products will depend on widespread <font color="blue">acceptance</font> of such     <font color="blue">products by doctors</font> and <font color="blue">clinicians</font></td>
    </tr>
    <tr>
      <td>The use of products to <font color="blue">assess genetic</font>     variation, gene expression or identify <font color="blue">infectious diseases</font> is <font color="blue">relatively new</font>     and <font color="blue">remains uncertain</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">clinicians</font> and doctors do not adopt our products,     our  business,  financial  condition and results of <font color="blue">operation could</font> be     <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>In these events, our <font color="blue">stock <font color="blue">price would likely decline</font></font></td>
    </tr>
    <tr>
      <td>WE HAVE LIMITED MANUFACTURING EXPERIENCE AND MAY NEED TO MODIFY, EXPAND OR     ESTABLISH NEW MANUFACTURING FACILITIES AS WE COMMERCIALIZE OUR PRODUCTS       We have limited experience <font color="blue">manufacturing</font> our products and have limited     experience <font color="blue">manufacturing</font> our products in the volumes that will be <font color="blue">necessary</font>     for us to achieve <font color="blue">significant</font> commercial sales</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">establish new</font>     <font color="blue">manufacturing</font>  processes or <font color="blue">facilities</font>, modify existing <font color="blue">facilities</font> and     processes,  or  outsource  product component <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Facilities     </font>expansion  and  <font color="blue">development</font>,  process  <font color="blue">improvements</font>,  and  outsourcing     <font color="blue">manufacturing</font>  can  be  <font color="blue">delayed by unforeseen circumstances</font>, including     <font color="blue">inability</font>  to obtain needed <font color="blue">manufacturing</font> equipment on a <font color="blue">timely basis</font>,     <font color="blue">difficulties with facility construction</font> and <font color="blue">completion</font> of <font color="blue">improvements</font> and     <font color="blue">difficulties incorporating new processes</font> and <font color="blue">vendor supply issues associated</font>     with component outsourcing</td>
    </tr>
    <tr>
      <td>If we fail to meet our <font color="blue">manufacturing</font> needs, we     may not be able to provide our <font color="blue">customers with</font> the quantity of products they     require,  which  <font color="blue">would damage customer relations</font> and result in reduced     revenues</td>
    </tr>
    <tr>
      <td>Additionally, some of our <font color="blue">products must</font> be                                         13       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font><font color="blue">manufacture</font>d in <font color="blue"><font color="blue">accordance</font> with</font> the FDA’s QSRs</td>
    </tr>
    <tr>
      <td>We have limited experience     in <font color="blue">manufacturing</font> our products in <font color="blue">compliance with</font> QSRs and <font color="blue">cannot guarantee</font>     that our <font color="blue">manufacturing</font> and production systems are in <font color="blue">compliance with</font> the     QSRs</td>
    </tr>
    <tr>
      <td>Key <font color="blue">components</font> of our <font color="blue">products may</font> be <font color="blue">sourced from</font> a <font color="blue">single supplier</font> or a     limited number of suppliers</td>
    </tr>
    <tr>
      <td>Specifically, <font color="blue">oligonucleotides</font> for many of our     <font color="blue">research use only products</font> are <font color="blue">sourced from</font> a <font color="blue">single supplier</font> as are certain     <font color="blue">components</font> of our InPlex <font color="blue">microfluidic card format</font></td>
    </tr>
    <tr>
      <td>In addition, some of the     <font color="blue">components</font> incorporated into our <font color="blue">products may</font> be <font color="blue">proprietary</font> and unavailable     <font color="blue">from secondary sources</font></td>
    </tr>
    <tr>
      <td>Finally, to comply with QSRs, we must verify that     our suppliers of key <font color="blue">components</font> are in <font color="blue">compliance with</font> all applicable FDA     <font color="blue">regulations</font> and meet our standards for quality</td>
    </tr>
    <tr>
      <td>If we lose a source of     supply due to any of the above reasons or otherwise we may not be able to     arrange for <font color="blue">alternative supply sources</font></td>
    </tr>
    <tr>
      <td>If our suppliers are unable or     unwilling  to  supply  us  on commercially acceptable terms with these     <font color="blue">components</font>, we may be unable to <font color="blue">satisfy demand</font> for our <font color="blue">product on reasonable</font>     terms,  if  at  all, which may have an adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR LIMITED SALES AND MARKETING EXPERIENCE AND CAPACITY MAY ADVERSELY AFFECT     OUR ABILITY TO GROW AND TO COMPETE SUCCESSFULLY IN COMMERCIALIZING OUR     POTENTIAL PRODUCTS       Our <font color="blue">sales force consists</font> of 18 individuals focused on direct sales and 15     <font color="blue">individuals focused on service</font> and support in the <font color="blue">clinical market</font></td>
    </tr>
    <tr>
      <td>We may     need to increase the size of our <font color="blue">sales force as</font> we <font color="blue">further <font color="blue">commercialize</font></font> our     products, and we may not be able to recruit, hire and train a sufficient     number of <font color="blue">sales personnel</font> in a short time frame</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also market</font> our     <font color="blue">products through <font color="blue">collaboration</font>s</font> and <font color="blue"><font color="blue">distribution</font> <font color="blue">agreements</font> with diagnostic</font>,     <font color="blue">biopharmaceutical</font> and <font color="blue">life science companies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that we     will  be  able  to  establish a <font color="blue">successful sales force</font> or to establish     <font color="blue">collaboration</font> or <font color="blue"><font color="blue">distribution</font> arrangements</font> to market our products</td>
    </tr>
    <tr>
      <td>If we are     unable to implement an <font color="blue"><font color="blue">effective</font> marketing</font> and <font color="blue">sales strategy</font>, we will be     unable to grow our revenues and execute our business plan</td>
    </tr>
    <tr>
      <td>This would have     an  adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have limited experience with sales of our <font color="blue">clinical molecular <font color="blue">diagnostics</font></font>     <font color="blue">products outside</font> of the US We <font color="blue">cannot guarantee</font> that we will <font color="blue">successfully</font>     develop sales, <font color="blue">distribution</font>, product and <font color="blue">customer support capabilities</font>     <font color="blue">internationally</font> that <font color="blue">will enable us</font> to generate <font color="blue">significant</font> revenue from     sales  outside  the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition, sales made outside the     US are subject to foreign <font color="blue">regulations</font> typical to the sale and marketing of     our products that may pose an <font color="blue">additional risk</font> for us</td>
    </tr>
    <tr>
      <td>If we fail to increase     our <font color="blue">revenues from sales outside</font> of the <font color="blue">United States</font>, this would have an     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">customer base</font> is <font color="blue">dominated by</font> a small number of large <font color="blue">clinical testing</font>     <font color="blue">laboratories</font> (Quest Diagnostics, Inc, Specialty Laboratories, Inc, Mayo     Medical Laboratories, Kaiser Permanente, and Berkeley Heart Laboratories)     and  research customers (University of Tokyo/RIKEN and Pioneer Hi-Bred     International, Inc</td>
    </tr>
    <tr>
      <td>We regularly experience pricing and other <font color="blue">competitive</font>     pressures in these <font color="blue">accounts</font></td>
    </tr>
    <tr>
      <td>Many of our contracts <font color="blue">with key customers</font> are     short-term contracts and/or subject to early <font color="blue">termination</font></td>
    </tr>
    <tr>
      <td>Our customers are     not obligated to <font color="blue">renew contracts</font> after they expire</td>
    </tr>
    <tr>
      <td>If, for any reason, we     are unable to maintain or renew our contracts, particularly our contracts     <font color="blue">with key customers</font>, or if, for any reason, we are unable to maintain current     pricing levels and/or volumes with our customers, our revenues and business     <font color="blue">may suffer materially</font></td>
    </tr>
    <tr>
      <td>THE EARLY TERMINATION OF ANY OF OUR STRATEGIC COLLABORATION OR CUSTOMER     SUPPLY AGREEMENTS COULD SERIOUSLY HARM OUR BUSINESS AND FINANCIAL CONDITION       Certain  of our strategic, research <font color="blue">collaboration</font>, and customer supply     <font color="blue">agreements</font> may be terminated with little or no notice</td>
    </tr>
    <tr>
      <td>In particular, the     supply of products to Japanese <font color="blue">customers may</font> be <font color="blue">terminated upon specified</font>     notice at any time</td>
    </tr>
    <tr>
      <td>These <font color="blue">customers will likely account</font> for a material     portion of our revenues for 2006</td>
    </tr>
    <tr>
      <td>Accordingly, early <font color="blue">termination</font> of these     <font color="blue">relationships</font> and supply <font color="blue">agreements</font> would seriously harm our revenues, and     in turn, our business, and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>WE MAY REQUIRE ADDITIONAL FINANCING FOR OUR FUTURE OPERATING PLANS     FINANCING MAY NOT BE AVAILABLE ON ACCEPTABLE TERMS, IF AT ALL       We may need to <font color="blue">raise <font color="blue">additional capital</font></font> in the future</td>
    </tr>
    <tr>
      <td>We have expended     <font color="blue">significant</font> resources and expect to continue to expend <font color="blue">significant</font> resources     in our research and product <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> activities</font> and     to improve production processes, litigate <font color="blue">intellectual</font> property disputes,     and seek FDA clearance or approvals</td>
    </tr>
    <tr>
      <td>The amount of <font color="blue">additional capital</font> we     will need to <font color="blue">raise will depend on</font> many factors, including:         •  our progress with our research and <font color="blue">development</font> programs;         •  the needs we may have to pursue FDA <font color="blue">clearances</font> or approvals of our     products;         •  our level of success in selling our products and <font color="blue">technologies</font>;         •  our ability to establish and maintain successful <font color="blue">collaboration</font>s;         •  the costs we incur in securing <font color="blue"><font color="blue">intellectual</font> property rights</font>, whether     through patents, licenses or otherwise;         •  the costs we incur in enforcing and defending our patent claims and     other <font color="blue"><font color="blue">intellectual</font> property rights</font>;         •  the timing of purchases of <font color="blue">additional capital</font>;         •  the need to respond to <font color="blue">competitive</font> pressures; and         •  the <font color="blue">possible acquisition</font> of <font color="blue">complementary</font> products, businesses or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise additional funds through</font> the sale of equity, convertible debt or     other equity-linked securities, our shareholders’ percentage ownership in     the Company will be reduced</td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">transactions may dilute</font> the     value of our <font color="blue">outstanding stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may issue securities</font> that have rights,     <font color="blue">preferences</font>  and  privileges  senior  to our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we raise     additional funds through <font color="blue">collaboration</font>s or <font color="blue">licensing arrangements</font>, we may     <font color="blue">relinquish rights</font> to certain of our <font color="blue">technologies</font> or products, or grant     licenses to <font color="blue">third parties on terms</font> that are unfavorable to us</td>
    </tr>
    <tr>
      <td>If future     financing is not available to us or is not <font color="blue">available on terms</font> acceptable to     us, we may not be able to fund our future needs that would have an adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>FAILURE  TO  MAINTAIN  EFFECTIVE  INTERNAL CONTROLS IN ACCORDANCE WITH     SECTION 404 OF THE SARBANES-OXLEY ACT COULD HAVE A MATERIAL ADVERSE EFFECT     ON OUR BUSINESS AND STOCK PRICE       If we fail to maintain adequacy of our internal controls in <font color="blue"><font color="blue">accordance</font> with</font>     the <font color="blue">requirements</font> of Section 404 of the Sarbanes-Oxley Act of 2002 and as     such standards are modified, supplemented or amended from time to time, we     may not be able to ensure that we can conclude on an ongoing basis that we     have <font color="blue">effective</font> internal controls over financial reporting in <font color="blue"><font color="blue">accordance</font> with</font>     Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>Failure to achieve and maintain an     <font color="blue">effective</font> internal control <font color="blue">environment</font> could have a material adverse effect     on our stock price</td>
    </tr>
    <tr>
      <td>COMMERCIALIZATION OF OUR TECHNOLOGIES MAY DEPEND ON STRATEGIC PARTNERSHIPS     AND  COLLABORATIONS WITH OTHER COMPANIES, AND IF OUR CURRENT OR FUTURE     PARTNERSHIPS  AND COLLABORATIONS ARE NOT SUCCESSFUL, WE MAY EXPERIENCE     DIFFICULTY COMMERCIALIZING OUR TECHNOLOGIES AND PRODUCTS       In order to augment our <font color="blue">internal sales</font> and <font color="blue">marketing efforts</font> and to reach     <font color="blue">additional product</font> and <font color="blue">geographic markets</font>, we have <font color="blue">entered into</font> or may enter     into  strategic  <font color="blue">partnerships</font>  and <font color="blue">collaboration</font>s for the <font color="blue">development</font>,     marketing, sales or <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> provide     us, in some instances, with <font color="blue">distribution</font> of our products, access to products     and <font color="blue">technologies</font> that are <font color="blue">complementary</font> to ours and funding for <font color="blue">development</font>     of our products</td>
    </tr>
    <tr>
      <td>We may also be <font color="blue">dependent on <font color="blue">collaborators</font></font> for <font color="blue">regulatory</font>     approvals and <font color="blue">clearances</font>, and <font color="blue">manufacturing</font> in <font color="blue">particular geographic</font> and     <font color="blue">product markets</font></td>
    </tr>
    <tr>
      <td>If our strategic <font color="blue">partnerships</font> and <font color="blue">collaboration</font>s are not     successful, we may not be able to develop or <font color="blue">successfully</font> <font color="blue">commercialize</font> the     products that are the subject of the <font color="blue">collaboration</font>s on a <font color="blue">timely basis</font>, if at     all, or <font color="blue">effective</font>ly distribute our products</td>
    </tr>
    <tr>
      <td>In addition, if we do not enter     into additional partnership <font color="blue">agreements</font>, or if these <font color="blue">agreements</font> are not     successful, our ability to develop, <font color="blue">commercialize</font> and <font color="blue">distribute products</font>     will be <font color="blue">negatively affected which will harm</font> our future operating results</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>We have <font color="blue">no control over</font> the resources that any partner or <font color="blue">collaborator may</font>     devote  to  our  products</td>
    </tr>
    <tr>
      <td>Any  of  our present or future partners or     <font color="blue">collaborators</font> may not perform their <font color="blue">obligations</font> as expected</td>
    </tr>
    <tr>
      <td>These partners     or  <font color="blue">collaborators</font>  may breach or terminate their <font color="blue">agreements</font> with us or     <font color="blue">otherwise fail</font> to meet their <font color="blue">obligations</font> or perform their <font color="blue">collaborative</font>     activities <font color="blue">successfully</font> and in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Further, any of our partners     or  <font color="blue">collaborators</font> may elect not to develop products arising out of our     <font color="blue">partnerships</font>  or  <font color="blue">collaboration</font>s or <font color="blue">devote sufficient resources</font> to the     <font color="blue">development</font>,  <font color="blue">manufacture</font>,  <font color="blue">commercialization</font> or <font color="blue">distribution</font> of these     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not be able to develop our     products  and  <font color="blue">technologies</font>  and our ability to generate <font color="blue">revenues will</font>     decrease</td>
    </tr>
    <tr>
      <td>WE  ARE  IN A HIGHLY COMPETITIVE INDUSTRY AND MARKETPLACE COMPETITIVE     DEVELOPMENTS, INCLUDING NEW TECHNOLOGIES THAT RENDER OURS LESS COMPETITIVE     OR OBSOLETE, COULD SERIOUSLY HARM OUR BUSINESS       The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">life sciences industries generally</font> and the genetic     analysis  and  molecular  <font color="blue">diagnostics</font>  <font color="blue">markets specifically</font> are highly     <font color="blue">competitive</font>, and we expect the intensity of <font color="blue">competition</font> to increase</td>
    </tr>
    <tr>
      <td>We     <font color="blue"><font color="blue">compete with</font> <font color="blue">organizations</font></font> in the <font color="blue">United States</font> and abroad that develop and     <font color="blue">manufacture</font>  products and provide services for the analysis of genetic     information for research and/or clinical applications</td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font>     include:         •  diagnostic, <font color="blue">bio<font color="blue">technology</font></font>, pharmaceutical, healthcare, chemical and     other companies;         •  academic and <font color="blue">scientific institutions</font>;         •  <font color="blue">governmental agencies</font>;         •  public and private research <font color="blue">organizations</font>; and         •  <font color="blue">clinical labs</font></td>
    </tr>
    <tr>
      <td>Many  of  our <font color="blue">competitors</font> have greater financial, technical, research,     marketing, sales, <font color="blue">distribution</font>, service and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">competitors</font> may offer broader product lines and have greater     name  <font color="blue">recognition than</font> we do, and <font color="blue">may offer discounts as</font> a <font color="blue">competitive</font>     tactic</td>
    </tr>
    <tr>
      <td>In addition, several <font color="blue">development</font> stage companies are currently     making or developing <font color="blue">technologies</font>, products or services that <font color="blue">compete with</font> or     are  being designed to <font color="blue">compete with</font> our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may develop or market <font color="blue">technologies</font>, products or services that     are more <font color="blue">effective</font> or <font color="blue">commercially attractive than</font> our current or future     products, or that may render our <font color="blue">technologies</font> or products less <font color="blue">competitive</font>     or obsolete</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may make rapid technological <font color="blue">development</font>s which may     result in our <font color="blue">technologies</font> and <font color="blue">products becoming obsolete</font> before we recover     the <font color="blue">expenses incurred</font> to develop them or before they generate <font color="blue">significant</font>     revenue  or  market <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may also obtain <font color="blue">regulatory</font>     advances or approvals of their <font color="blue">diagnostic products</font> more <font color="blue">rapidly than</font> we do</td>
    </tr>
    <tr>
      <td>Accordingly, if <font color="blue">competitors</font> introduce superior <font color="blue">technologies</font> or products or     obtain <font color="blue">regulatory</font> approvals or <font color="blue">clearances</font> quicker than we do, and we cannot     make <font color="blue">enhancements</font> to our <font color="blue">technologies</font> and products <font color="blue">necessary</font> for them to     remain <font color="blue">competitive</font>, our <font color="blue"><font color="blue">competitive</font> position</font>, and in turn our business,     revenues and <font color="blue">financial condition</font>, will be <font color="blue">seriously harmed</font></td>
    </tr>
    <tr>
      <td>Our existing and potential <font color="blue">competitors</font> may be in the process of seeking FDA     or foreign <font color="blue">regulatory</font> approval for their respective products or may also     enjoy substantial <font color="blue">advantages</font> over us in terms of research and <font color="blue">development</font>     expertise, clinical trial expertise, experience in submission of products to     <font color="blue">regulatory</font>  <font color="blue">authorities</font>  and the marketing or <font color="blue">commercialization</font> of FDA     approved or <font color="blue">cleared products</font></td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue">competitors</font> may have     or will establish third-party <font color="blue">reimbursement</font> for their products</td>
    </tr>
    <tr>
      <td>We may not     be  able  to compete <font color="blue">effective</font>ly against <font color="blue">competitors</font> that hold such an     advantage  which  may  have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE MAY BE UNABLE TO PROTECT OUR PROPRIETARY METHODS AND TECHNOLOGIES AND MAY     BE SUBJECT TO CLAIMS OF INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF     OTHERS       Our <font color="blue">commercial success will depend</font>, to a <font color="blue">significant</font> degree, on our ability     to obtain <font color="blue">patent protection on</font> many aspects of our business, including the     products, methods and services we develop</td>
    </tr>
    <tr>
      <td>Patents issued to us may not                                         16       _________________________________________________________________    [73]Table of <font color="blue">Contents       </font><font color="blue">provide us with</font> substantial protection or be <font color="blue">commercially beneficial</font> to us</td>
    </tr>
    <tr>
      <td>The  issuance  of a patent is not <font color="blue">conclusive as</font> to its validity or its     <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">patent applications</font> or those we have     licensed, may not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">patent applications</font> do     not  result  in  issued  patents, our <font color="blue">competitors</font> may obtain rights to     <font color="blue">commercialize</font> our <font color="blue">discoveries which would harm</font> our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also may apply</font> for <font color="blue">patent protection on</font> novel <font color="blue">genetic <font color="blue">variations</font></font> in known     genes  and their uses, as well as novel uses for <font color="blue">previously</font> identified     <font color="blue">genetic <font color="blue">variations</font></font> discovered by third parties</td>
    </tr>
    <tr>
      <td>In the latter cases or in     the area of new product <font color="blue">development</font>, we may need <font color="blue">licenses from</font> the holders     of <font color="blue">patents with respect</font> to such <font color="blue">genetic <font color="blue">variations</font></font> in order to make, use or     sell any related products</td>
    </tr>
    <tr>
      <td>We may not be able to acquire <font color="blue">such licenses on</font>     terms acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>Certain parties are attempting to rapidly identify and <font color="blue">characterize genes</font>     and <font color="blue">genetic <font color="blue">variations</font></font> through the use of sequencing and other <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>To the extent any patents are issued to other <font color="blue">parties on such partial</font> or     full-length genes or <font color="blue">genetic <font color="blue">variations</font></font> or uses for such genes or genetic     <font color="blue">variations</font>, the <font color="blue">risk increases</font> that the sale of products developed by us or     our <font color="blue">collaborators</font> may give rise to claims of <font color="blue">patent infringement against us</font></td>
    </tr>
    <tr>
      <td>Others  may  have  filed and, in the future, are likely to <font color="blue">file patent</font>     <font color="blue">applications covering</font> many <font color="blue">genetic <font color="blue">variations</font></font> and their uses</td>
    </tr>
    <tr>
      <td>Others may     file and, in the future, may file, <font color="blue">patent applications</font> covering <font color="blue">improvements</font>     to our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such patent application may</font> have <font color="blue">priority over</font> our     <font color="blue">patent applications</font> and <font color="blue">could further restrict</font> our ability to market our     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any license that we may require under     any <font color="blue">such patent will</font> be made available to <font color="blue">us on commercially</font> acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>While we believe our <font color="blue">technology</font> does not infringe any <font color="blue">third party rights</font>, we     have  in  the <font color="blue">past been party</font> to and are <font color="blue">currently party</font> to <font color="blue">litigation</font>     involving  patents  and  <font color="blue">intellectual</font>  property  rights</td>
    </tr>
  </tbody>
</table>